#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary mediastinal large B-cell lymphoma Infection in an immunocompromised host Nasopharyngeal cancer Primary amyloidosis Laryngeal squamous cell carcinoma Von Hippel-Lindau disease Anal cancer Eosinophilic oesophagitis Myelin oligodendrocyte glycoprotein antibody-associated disease Congenital generalised lipodystrophy Deafness neurosensory Oesophageal adenocarcinoma stage II Neurofibromatosis Leukaemia Squamous cell carcinoma of the hypopharynx More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Synovial sarcoma metastatic – Life with Disease Synovial sarcoma metastatic – Diagnostics Synovial sarcoma metastatic – Treatment Piriformis syndrome – Treatment Pituitary-dependent Cushing’s syndrome – Diagnostics Stevens-Johnson syndrome – Diagnostics Bronchopulmonary dysplasia – Diagnostics Waldenstrom’s macroglobulinaemia recurrent – Life with Disease Nephrotic syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Levofloxacin Hydrocortisone AMO959 Sodium Iotalamate (125I) Vixarelimab Bi 1819479 Radotinib Dihydrochloride Eteplirsen Danicopan Ivospemin Iron PICLIDENOSON Bio89-100 Ds-2325A Vb10.16 Timothy Grass Pollen Extract Methionine Buclizine Hydrochloride Alizapride GSKVX000000025896 More therapies…

    Learn about Your Condition

    Muscle strain Synovial sarcoma recurrent Obsessive-compulsive disorder Metabolic syndrome Eosinophilic oesophagitis Angiosarcoma recurrent Chronic kidney disease Cardiac failure congestive Bronchiolitis Hyperplasia adrenal Diminished ovarian reserve Mucous membrane pemphigoid PIK3CA-activated mutation Stomatitis Colorectal adenocarcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Epilepsy

  • Study on the Safety and Effectiveness of Sirolimus and Vigabatrin for Preventing Symptoms in Infants with Tuberous Sclerosis Complex

    Recruiting

    4 1 1
    Investigated Diseases:
    • Tuberous sclerosis complex
    • Epilepsy
    Investigated Drugs:
    • Vigabatrin
    • Sirolimus
    Poland

  • Study on the Effectiveness and Safety of Sirolimus for Patients with Drug-Resistant Epilepsy Linked to Tuberous Sclerosis Complex

    Recruiting

    3 1 1
    Investigated Diseases:
    • Tuberous sclerosis complex
    • Epilepsy
    Investigated Drugs:
    • Sirolimus
    Poland

  • Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Epilepsy
    Investigated Drugs:
    • Levetiracetam
    Bulgaria Czechia Germany Greece Hungary Italy +3

  • Study on Cannabidiol and Dronabinol for Children with Refractory Epilepsy

    Recruiting

    3 1
    Investigated Diseases:
    • Epilepsy
    Investigated Drugs:
    • Dronabinol
    • Cannabidiol
    The Netherlands

  • Study on Clioquinol for Reducing Seizures in Patients with Drug-Resistant Epilepsy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Epilepsy
    Investigated Drugs:
    • Clioquinol
    Belgium

  • Phase 2 Study Evaluating OV329 on Photo‑Induced EEG Response in Adults with Epilepsy

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Epilepsy
    The Netherlands
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!